Clinical & Experimental Metastasis

, Volume 20, Issue 1, pp 51–58

Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation

  • Yasuharu Onishi
  • Kazuhiro Tsukada
  • Jun Yokota
  • Avraham Raz


Autocrine motility factor receptor (AMFR) is a cell surface glycoprotein of 78000 molecular weight (gp78), regulating cell motility signaling in vitro and metastasis in vivo. To test whether AMFR could be a common mediator of transformation and oncogenic itself, we transfected NIH3T3 fibroblast cells with expression vectors carrying the full-length cDNA for mouse AMFR and evaluated the effects of increased AMFR on transforming potential. The cells stably expressing high levels of AMFR as a result of transfection displayed a complete morphological change and acquired the ability to grow even in low serum. Furthermore, they were anchorage-independent for growth in soft agar and more motile in phagokinetic track assay. Interestingly, the enhanced expression of AMFR produced tumors in nude mice. Our findings provide a direct evidence that overexpression of the AMFR is associated with the acquisition of a transformation phenotype.

motility transformation tumorigenicity phosphohexose isomerase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Downward J, Yarden Y, Mayes E et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521–7.Google Scholar
  2. 2.
    Sherr CJ, Rettenmier CW, Sacca R et al. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985; 41: 665–76.Google Scholar
  3. 3.
    Hunter T. Cooperation between oncogenes. Cell 1991; 64: 249–70.Google Scholar
  4. 4.
    Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271–80.Google Scholar
  5. 5.
    Di Fiore PP, Pierce JH, Kraus MH et al. erbR-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178–82.Google Scholar
  6. 6.
    Velu TJ, Beguinot L, Vass WC et al. Epidermal growth factordependent transformation by a human EGF receptor proto-oncogene. Science 1987; 238: 1408–10.Google Scholar
  7. 7.
    Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159–63.Google Scholar
  8. 8.
    Liotta LA, Mandler R, Murano G et al. Tumor autocrine motility factor. Proc Natl Acad Sci USA 1986; 83: 3302–06.Google Scholar
  9. 9.
    Watanabe H, Takehara K, Date M et al. Tumor cell autocrine motility factor is the neyroleukin/phosphohexose isomerase polypeptide. Cancer Res 1996; 56: 2960–63.Google Scholar
  10. 10.
    Niinaka Y, Paku S, Haga A et al. Expression and secretion of neyroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. Cancer Res 1998; 58: 2667–74.Google Scholar
  11. 11.
    Xu W, Seiter K, Feldman E et al. The differenciation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphohexose isomerase. Blood 1996; 87: 4502–06.Google Scholar
  12. 12.
    Chiao JW, Xu W. Seiter K et al. Neuroleukin mediated differentiation induction of myelogenous leukemia cells. Leuk Res 1999; 23: 13–8.Google Scholar
  13. 13.
    Funasaka T, Haga A, Raz A et al. Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility. Biochem Biophys Res Commun 2001; 285: 118–28.Google Scholar
  14. 14.
    Onishi Y, Haga A, Raz A. Autocrine motility factor (AMF) and AMF receptor as regulators of metastasis. Cancer Metastasis Biol Treat (in press).Google Scholar
  15. 15.
    Stracke ML, Engel JD, Wilson LW et al. The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. J Biol Chem 1989; 264: 21544–9.Google Scholar
  16. 16.
    Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res 1990; 50: 409–14.Google Scholar
  17. 17.
    Watanabe H, Nabi IR, Raz A. The relationship between motility factor receptor internalization and the lung colonization capability of murine melanoma cells. Cancer Res 1991; 51: 2699–705.Google Scholar
  18. 18.
    Kohn EC, Liotta LA, Schiffman E. Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells. Biochem Biophys Res Commun 1990; 166: 757–64.Google Scholar
  19. 19.
    Watanabe H, Carmi P, Hogan V et al. Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 1991; 266: 13442–8.Google Scholar
  20. 20.
    Timar J, Silletti S, Bazaz R et al. Regulation of melanoma cell motility by the lipoxygenase metabolite 12-(S)-HETE. Int J Cancer 1993; 55: 1003–10.Google Scholar
  21. 21.
    Silletti S, Timar J, Honn KV et al. Autocrine motility factor induces differential 12-lipovygenase expression and activity in high and lowmetastasis K-1735 melanoma cell variants. Cancer Res 1994; 54: 5752–6.Google Scholar
  22. 22.
    Nakamori S, Watanabe H, Kameyama M et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer (Phila) 1994; 74: 1855–62.Google Scholar
  23. 23.
    Otto T, Birchmeier W, Schmidt U et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as prognostic factor in patients with bladder carcinoma. Cancer Res 1994; 54: 3120–3.Google Scholar
  24. 24.
    Maruyama K, Watanabe H, Shiozaki H et al. Expression of autocrine motility factor receptor in human esophageal aquamous cell carcinoma. Int J Cancer 1995; 64: 316–21.Google Scholar
  25. 25.
    Hirono Y, Fushida S, Yonemura Y et al. Expression of autocrine motility factor correlates with disease pregression in human gastric cancer. Br J Cancer 1996; 74: 2003–7.Google Scholar
  26. 26.
    Nagai Y, Ishikawa O, Miyachi Y et al. Expression of autocrine motility factor receptor in cutaneous malignant. Dermatology 1996; 192: 8–11.Google Scholar
  27. 27.
    Taniguchi K, Yonemura Y, Nojima N et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 1998; 82: 2112–2.Google Scholar
  28. 28.
    Shimizu K, Tani M, Watanabe H et al. The autocrine motility factor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999; 456: 295–300.Google Scholar
  29. 29.
    Freemont PS. The RING finger. A novel protein sequence motif related to the zinc finger. Ann NY Acad Sci 1993; 684: 174–92.Google Scholar
  30. 30.
    Landschulz WH, Johnson PF, McKnight SL. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 1988; 240: 1759–64.Google Scholar
  31. 31.
    Bussolino F, Di Renzo MF, Ziche M et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119: 629–41.Google Scholar
  32. 32.
    Shing Y, Christofori G, Hanahan D et al. Betacellulin: A mitogen from pancreatic beta cell tumors. Science 1993; 259: 1604–7.Google Scholar
  33. 33.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70.Google Scholar
  34. 34.
    Nabi IR, Watanabe H, Raz A. Autocrine motility factor and its receptor: Role in cell locomotion and metastasis. Cancer Metastasis Rev 1992; 11: 5–20.Google Scholar
  35. 35.
    Silletti S, Watanabe H, Carmi P et al. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 1991; 51: 3507–11.Google Scholar
  36. 36.
    Silletti S, Raz A. Regulation of autocrine motility factor receptor expression in tumor cell locomotion anf mertastasis. Curr TopMicrobiol Immunol 1996; 213: 137–69.Google Scholar
  37. 37.
    Freedman VH, Shin S. Cellular tumorigenicity in nude mice: Correlation with cell growth in semi-solid medium. Cell 1974; 3: 355–9.Google Scholar
  38. 38.
    Fedi, P Tronick SR, Aaroson SA, Growth factors. In Holland JF, Bast RC, Morton DL, Frei E, Kufe DW, Weichselbaum RR(eds): Cancer Medicine. Baltimore, Maryland: Williams and Wilkins 1997; 41–64.Google Scholar

Copyright information

© Kluwer Academic Publishers 2003

Authors and Affiliations

  • Yasuharu Onishi
    • 1
    • 2
  • Kazuhiro Tsukada
    • 2
  • Jun Yokota
    • 3
  • Avraham Raz
    • 1
    • 4
  1. 1.Tumor Progression and Metastasis ProgramKarmanos Cancer InstituteDetroitUSA
  2. 2.Second Department of Surgery, Faculty of MedicineToyama Medical and Pharmaceutical UniversityToyamaJapan
  3. 3.Biology DivisionNational Cancer Center Research InstituteTokyoJapan
  4. 4.Department of Pathology and Radiation OncologyWayne State University School of MedicineDetroitUSA

Personalised recommendations